Although some risk factors for accelerated decline in forced expiratory volume in 1 s (FEVi) such as cigarette smoking, are well defined, it is not possible to identify those individuals with the most rapid rates of decline. Von Willebrand factor (vWF) is a product of both the pulmonary and systemic endothelium, and serum levels are raised during episodes of acute bronchitis. We hypothesized that raised serum levels of vWF may indicate sub-clinical pulmonary injury and so may predict subsequent accelerated decline in FEVi. The aims of this study were 1. to define the prevalence of chronic respiratory symptoms and obstructive airway disease in an inner-city British population and 2. to determine whether elevated levels of von Willebrand factor (vWF) identify those individuals at risk for more rapid decline in FEVi over time.
Introduction
Chronic obstructive pulmonary disease (COPD) and asthma remain significant causes of morbidity and mortality in Britain. Cigarette smoking is irrefutably linked to the development of COPD (1, 2) , although the pathophysiological mechanisms remain poorly defined. Fletcher and Peto (1) demonstrated that FEVt declines progressively after the age of 25-30 at a rate of about 30 ml yr-'. Cigarette smoking roughly doubles this rate of decline, but does not 0954-6111/99/100726+08 $12+lO/O accelerate decline sufficiently to lead to disabling shortness of breath unless another factor (or factors) are present. These contributing factors are unknown, but are present in 15-20% of smokers (the so-called 'susceptible' smokers) (1,2) Bronchial hyper-reactivity and female sex were identified as additional risk factors by the U.S. Lung Health Study (3) , while Fletcher and Peto have shown that chronic mucus hypersecretion, while being independently due to cigarette smoking, is not a risk factor for airflow limitation (1) .
Most studies have demonstrated a recent decline in the prevalence of chronic obstructive pulmonary disease (COPD) and an increase in the prevalence of asthma (at least in children) (4) (5) (6) (7) , although these changes may in part reflect labelling shifts and cohort effects (7) . Obstructive lung diseases remain generally more common in Britain than in other western nations, and there are substantial VONWILLEBRANDFACTORANDLONGITLJDINALDECLINELN FEVi 727 regional differences within the U.K. (7) . In order to reduce the prevalence of COPD, it will be necessary to identify and eliminate aetiological factors: cigarette smoking aside, these remain undefined.
Von Willebrand factor (vWF) is an endothelial product which, when homeostasis is threatened, is released and activates platelets through binding to the membrane glycoproteins Gpl b and GpIIb-IIIa (8) . Irreversible platelet binding leads to the formation of a platelet plug. vWF is a product of both the systemic and pulmonary endothelium (9) and is also released in situations where endothelial damage or dysfunction is present or presumed (systemic and pulmonary hypertension (10) (11) (12) and hypercholesterolaemia (13)). vWF is also released, presumably from the pulmonary endothelium, in the acute respiratory distress syndrome (ARDS), and its release may predate the development of clinical or radiological signs of ARDS (14-16). As we have found increased plasma levels of vWF in patients with acute bronchitis (17) we hypothesized that higher serum levels of vWF may indicate sub-clinical pulmonary injury, and so may predict a more rapid rate of decline in FEV, in subsequent years.
The aims of this study were 1. to define the prevalence of chronic respiratory symptoms and obstructive airway disease in an inner-city British population and 2. to determine whether elevated blood levels of von Willebrand factor (vWF) identify those individuals at risk for more rapid decline in FEVi over time.
Material and methods
Both components of the study were passed by the East Birmingham Health Authority Research and Ethics Committee.
PREVALENCE STUDY

Subjects
In Autumn 1987, all 2013 individuals aged 45-74 years registered with an inner-city general practice (total practice population approximately 9500) were sent a respiratory symptom questionnaire and an invitation to attend for lung function tests (17) . Non-responders were re-mailed to a total of three mailings. From those who responded a one in six sample was selected (using random number tables) to attend for lung function and blood tests. This subgroup formed the longitudinal study population (see below).
Methods
The respiratory symptom questionnaire was adapted from that developed by the International Union Against Tuberculosis and Lung Disease (IUATLD) (18 Smoking histories were self-reported. In those who attended for lung function tests, smoking histories were obtained and exhaled carbon monoxide levels (Morgan Ecocheck) measured. One pack-year was defined as one pack of 20 cigarettes smoked per day for 1 yr. Lung function (FEVi and FVC) was assessed on one occasion using a VitalographTM dry-bellows spirometer, with at least two attempts reproducible to within 200 ml or 5% (whichever was smaller). Assessment was delayed until symptomatic recovery in patients with respiratory infections, but inhaled bronchodilators were not used, in common with previous studies of this type (19) (20) (21) . Those attending for spirometry had serum collected for assay of vWF, using an enzyme linked immunosorbent method (22) on three separate venous blood samples, each acquired at least a week apart.
Analysis
Discreet data are presented as numbers and percentages of the totals. Continuous data are presented as means and standard deviations. Percent of predicted values for lung function were calculated following the 1994 British Thoracic Society guidelines (23) . Chi-squared tests were used to assess differences in questionnaire responses according to smoking status for statistical significance. Multiple logistic regression analyses (STATA, Stata Corp, U.S.A.) were performed to identify questionnaire items independently associated with obstructive spirometry (FEVJFVC ~70%) and FEVi ~15% predicted.
LONGITUDINAL STUDY Subjects
The individuals who had lung function and vWF assessed in Autumn 1987 formed the longitudinal study population.
Methods
Follow-up was conducted in Autumn 1996 after a 9 yr interval. Patients were traced via their general practitioners and the local health authority. Those still in the Midlands area of the U.K. were asked to complete the same respiratory symptom questionnaire, and were requested to attend for further breathing tests (again with two reminders). Lung function (FEVr and FVC) was re-assessed by a different operator, but using the same VitalographTM dry-bellows spirometer and the same methodology as in 1987.
Analysis
Differences in the prevalence of respiratory symptoms in the prevalence study population and the longitudinal study population were assessed for statistical significance using Chi-squared tests. The characteristics of the populations with and without follow-up lung function data in the longitudinal study population were compared using ANO-VA for normally distributed data, Kruskal-Wallis one way analysis of variance for non-parametric data and chisquared tests for discreet variables. The mean of the three estimations of vWF (1987) were used in statistical analysis. Annualized rate of decline in FEVr was calculated for each individual by subtracting the FEVr in 1996 from the FEVr in 1987 (in ml) and dividing by the number of intervening decimal years (to the nearest month).
Given the heterogeneity of the study population, we also examined change in lung function in terms of annualized decline in FEVr height-'. Multiple logistic regression analyses (STATA, Stata Corp, U.S.A.) were performed to identify parameters assessed in 1987 which were associated with subsequent mortality, and to identify those parameters associated with upper quartile loss of FEV, and FEVr height-'. Differences in annualized decline in FEVr between different patient groups were assessed for statistical significance using Student's unpaired r-test. Correlation coefficients were obtained using the least squares method to look for an association between vWF levels and annualized decline in FEVr and FEV, height-'.
Results
PREVALENCE STUDY
One thousand five hundred and twenty seven of 2013 (758%) individuals completed the questionnaire in 1987.
The response rate was higher in females than in males (78.6% vs. 73.7%, P-cO.02) and in older patients (P<O.OOl). The characteristics of the 1527 responders are presented by smoking status in Table 1 . There was a high prevalence of chronic respiratory symptoms with 42.2% of responders reporting shortness of breath on hills, 34.7% reporting wheeze and 31.6% reporting mucus hypersecretion. Twenty-one percent of responders reported both mucus hypersecretion and shortness of breath on hills. Nine percent had a history of asthma. Current smokers and ex-smokers were more likely to be male and to report wheeze, mucus hypersecretion and shortness of breath on walking up a slight hill (Table 1) .
Of the 251 subjects approached to have lung function and blood tests, 210 (84%) had spirometry performed and serum vWF assayed in Autumn, 1987. The 41 subjects who did not have lung function assessed were slightly younger (although not statistically significantly so) than the 210 who did (median age 55 vs. 61, P=O.O9), but were similar in all other respects. The prevalence of chronic respiratory symptoms in this subgroup of 210 subjects who formed the longitudinal study population was not statistically significantly different to that in the prevalence study population (Table 1 and Table 2 ). Pulmonary function data reflected the questionnaire findings (Table 2) . Nineteen percent of patients (28% of men and 10% of women) had an FEVt ~75% of predicted and 23% (34% of men and 13% of women) had evidence of airways obstruction (FEVr/FVC < 70%). Twenty-three (11%) patients had both an FEV, ~75% of predicted and evidence of airflow limitation. Of these, seven (30%) had not seen a doctor regarding their chest for more than 2 yr.
The 39 patients with an FEVr ~75% predicted were older (62.6 years V.S. 59.5 years (P=O.O5)), and more likely to report wheeze (O.R. 9.8 (3.8-26.4)) and mucus hypersecretion (4.8(2%1-10.0) than those with normal lung function. There was a strong association between smoking status and having an FEV, ~75% predicted (3% of never smokers, 34% of ex-smokers and 13% of current smokers, P<O.OOOl). Those with airflow limitation (FEV,/ FVC<70%) were older (mean 64.9 years vs. 58.6 years (P<OaOOl)), more likely to be male (O.R. 3.6(16-8.3)) and had consumed a greater number of pack-years (37.5 vs. 21.6 (P<O.OOl)). +Probability that those followed up (n=l17) represent the same population as those lost to follow-up (n=61). 'Probability that those who died (n=32) represent the same population as those who lived or were lost to follow-up (n=178). SOB shortness of breath.
LONGITUDINAL STUDY
In Autumn 1996, 117 (56%) of the study population of 210 patients had pulmonary function re-assessed. Twenty-two (11%) could not be traced. A further 15 (7%) had moved from the Midlands area of the U.K., but were confirmed to be still alive. Twenty-four (11%) declined to attend for repeat spirometry. Thirty-two (15%) had died.
Deaths
Subjects who died (Table 2) were statistically significantly more likely to be male, to have a lower FEVi (both as average value and as % predicted) and to have a lower FVC (as % predicted) than survivors. Logistic regression analysis revealed FEVi < 75% of predicted to be a strong independent predictor of subsequent mortality, even when controlling for age, sex and smoking history (odds ratio 2.8 1 (1 e 14-6.93)). Neither vWF levels nor any questionnaire items were independently associated with subsequent mortality. Deaths were largely cardiovascular in nature rather than respiratory (eight from ischaemic heart disease, seven from carcinoma (other than lung), four from cerebrovascular accident, three from lung carcinoma, one from chronic obstructive pulmonary disease, three from other causes and six whose records were unobtainable).
Lung function decline
There were few differences between the baseline characteristics of groups with and without follow-up pulmonary function data, when those who died were excluded ( Table 2) . Thirty-eight percent of those lost to follow up had reported mucus hypersecretion in 1987, compared to 24% of those followed up (P=O.O5).
Of the 117 patients with longitudinal pulmonary function data, the average annualized decline in FEVi was 46.7 ml yr-' (range: a decline of 175.6 ml yt-' to a gain of 75.6 ml yr-'). The frequency distribution for annualized decline in FEVl inmlyr-' is presented in Fig. 1 . Four patients (3.4%) had a higher FEV, in 1996 than in 1987. After consulting their GPs it was found that two of these subjects suffered from mucus hypersecretion, but none had demonstrable reversible airway function. The decline in FEV, among never smokers, ex-smokers, persistent smokers, quitters, asthmatics and those with mucus hypersecretion is presented in *Mean (SD). +Mean (95% C.I.). Table 3 . None of the differences between these subgroups were statistically significant. Logistic regression analysis indicated that neither vWF levels nor any questionnaire items were independently associated with maximum (fourth quartile) loss of FEVi (or FEV height-') when age, sex, smoking status and starting FEVi were controlled for.
There was no significant correlation between vWF and subsequent rate of decline in FEVi or FEV heightd2. When examined individually, there was no correlation between vWF and rate of decline in FEVi in any of the patient subgroups.
Discussion
A number of conclusions can be drawn from this study in a sample of 45-75 year olds living in inner-city Birmingham.
Chronic respiratory symptoms were very common, and spirometric data revealed a high prevalence of airflow limitation associated with this symptomatology. Those patients with an FEVi ~75% predicted were older and more likely to report wheeze and mucus hypersecretion. Those with evidence of airflow limitation (FEVi/ FVC<75%) were also older and had consumed a greater number of pack-years. Much of this disease was unrecognized. FEVi ~75% of predicted was a strong independent predictor of subsequent (largely non-respiratory) mortality. The average annualized rate of decline (95% C.I.) in FEVt was 46.7 rnls yr-' (407-52.7), however, serum vWF levels were not correlated with subsequent rate of decline.
A number of potential criticisms need to be addressed. One is the representativeness of our study populations, given the initial (1987) response rate in the prevalence study and the numbers lost to follow-up in the longitudinal study. This problem is unavoidable in studies of this nature and can only be minimized through efforts such as the distribution of reminders (two in this case). In the longitudinal study, interim mortality introduces possible biases, but when this group was excluded there were few differences between those who were and those who were not followed up ( Table 2 ). The only statistically significant difference was an increased prevalence of mucus hypersecretion in the group lost to follow-up (P=O.O5). Importantly, however, there were no differences in vWF between the three groups, suggesting that our conclusions regarding vWF remain valid.
The prevalence of chronic respiratory symptoms in the 1527 patients who initially responded in 1987 was surprisingly high (Table 1 ) and was reflected in pulmonary function data ( Table 2 ). Much of this respiratory disease was unrecognized. A study by Littlejohns et al. (6) in southwest London, in a slightly younger population (age 40-70, n=1444), found an incidence of chronic bronchitis (as defined by the Medical Research Council questionnaire) of 17% in men and 7% women, considerably lower than our finding of persistent sputum production in 32.5% of the 1527 patients from inner-city Birmingham. A recent study in central Manchester (24) , in a population demographically similar to that in our study (mean age 66.1 years, n=723), found self-reported asthma or bronchitis to be present in 30.0% of the population. Both of these studies emphasize the prevalence of unrecognized chronic respiratory disease in these inner-city areas of the U.K.
One of the strongest independent predictors for subsequent mortality was FEV, < 75% of predicted, supporting previous observations concerning the importance of a low FEVl as an independent risk-factor not only for respiratory mortality, but all-cause mortality (25, 26) . The majority of deaths in our population were cardiovascular rather than respiratory. The aetiology of this association, which has been repeatedly described in the literature, remains unknown.
Among the 117 patients with longitudinal FEVl data the estimates of rate of decline in FEVl are in line with those described by Fletcher and Peto (1) but are greater than described by other (predominantly U.S.) studies (Table 4) . This may relate to the age of our study population as rate of TABLE 4. Annualized decline in FEVI, other studies decline in FEV, has been shown to accelerate with age (27, 28) . The small numbers in the patient subgroups listed in Table 3 precludes any positive conclusion being made regarding the relative rates of decline, according to smoking status or the presence of respiratory symptoms. The lack of an effect of smoking, may, in addition, relate to a type of 'survivor effect' [similar to that described by Camilli et al. (29) ] in this relatively elderly population, particularly since smoking status and FEVl were important independent predictors of interim mortality.
Our conclusions regarding annualized decline in FEVl require some qualification. The main criticisms are that we have only two data points, and that our range of starting values of FEVl is large, as expected in a heterogeneous population. The presence of only two data points precludes the use of regression models commonly used in longitudinal studies (27) and may contribute to the large range of annualized declines in FEVl found in this study. The assessment of relative decline in FEV, in a heterogeneous population is difficult, and models used to adjust for disparate starting FEVls are imperfect (20) . The model which most satisfactorily controls for body size is FEVl height-* (20) and accordingly we have described annualized decline in FEV, in these terms for comparison with serum vWF levels.
There are some positive factors in the study design which deserve mention. Although different operators assessed pulmonary function in 1987 and 1996, the methodology was standardized and the same spirometer was used throughout. Furthermore, although a learning effect is a common problem in longitudinal studies and is difficult to control for, the 9 yr interval between pulmonary function assessments meant that most patients had only a vague recollection of their previous visit, minimising the influence of learning.
Although a trend towards accelerated decline in FEVl amongst smokers was shown, this trend was not statistically significant. This may relate to the selection of a 'nonsusceptible' smoking population through interim mortality, and it may be argued that this effect has reduced the power of this study to detect an association between risk of accelerated decline in FEV, and vWF. However, the absence of even a trend towards showing this association for FEVi or FEVi heightd2 suggests that a type 2 statistical error is unlikely, but if present, the predictive value of vWF would be so slight as to be unhelpful to the clinician managing obstructive lung disease. In summary, the prevalence of chronic respiratory illness in the elderly living in the large cities of the U.K. remains high. Much of this disease is unrecognized. FEVt declines inexorably with age, but the rate of decline accelerates with cigarette smoking in a subgroup of patients. While a low FEVt remains a strong risk factor for subsequent respiratory and all-cause mortality, clinicians are currently unable to identify the subgroup of patients at risk for more rapid decline in FEVt. Measuring serum vWF levels would appear unhelpful in this regard.
